General Info

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that treat cancer, cardiovascular and autoimmune diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling. In structure-based drug design, scientists use detailed knowledge of the active sites of protein targets associated with particular diseases to design synthetic compounds that fight the disease. Structure-based drug design aims to create a molecule that will bind to the active site of a targeted enzyme, thereby preventing the normal chemical reaction and ultimately halting the progression of the disease. BioCryst was founded in 1986. The Company's stock is traded on the NASDAQ exchange under the symbol BCRX.